Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Cholecystokinin (CCK-8) peptide icon, one bubble per amino acidCholecystokinin (CCK-8)8 residuesDYMGWMDFEach bubble = one amino acid. Size = residue mass. Color = chemical class.

Cholecystokinin (CCK-8)

MetabolicFDA Approved
1.3 min half-life·Injection

Also known as: CCK-8S, CCK-8, sincalide

Your body already makes CCK-8 every time you eat fat or protein. This sulfated octapeptide fires from duodenal I-cells and tells your brain to stop eating, usually within minutes. Cholecystokinin (CCK-8) is one of the strongest short-term satiety signals in human physiology, and its synthetic twin sincalide (Kinevac) has been FDA-approved since 1976 for gallbladder imaging. The catch: a plasma half-life of about 1.3 minutes makes it nearly useless outside a clinical IV setting. Researchers still study it to understand appetite regulation and gut-brain signaling, but nobody is pinning this one at home.

What Is Cholecystokinin (CCK-8)?

A single IV infusion of CCK-8 cuts how much healthy men eat, and the effect grows with the dose. That finding, from Brennan and colleagues in a controlled study of 10 healthy men [1], captured what the gut already knew: cholecystokinin is the body's fastest brake on eating.

CCK-8 (also called CCK-8S for its sulfated form; CAS 25126-32-3) is the most bioactive circulating fragment of the 33-amino-acid hormone cholecystokinin, first isolated from porcine intestinal mucosa in the 1960s. Duodenal and jejunal I-cells release it within minutes of detecting dietary fat and protein. It locks onto CCK1 receptors on vagal nerve endings and sends satiety signals straight to the brainstem. Simultaneously, it contracts the gallbladder, pumps pancreatic enzymes, and slows gastric emptying. Think of it as a coordinated digestive and satiety broadcast that peaks in under 15 minutes and vanishes in under five.

The synthetic version, sincalide (Kinevac), received FDA approval in 1976 for gallbladder ejection fraction testing. Radiologists still use it daily. Native CCK-8 has no therapeutic approval; its half-life of about 1.3 minutes (PMID 4014106 (opens in a new tab)) and IV-only validated route make chronic dosing impractical. Rehfeld's 2025 review [2] confirmed that current obesity research has shifted toward protease-resistant CCK1-selective analogs rather than native CCK-8. Community use is nonexistent: zero Reddit threads, zero biohacker protocols, zero self-administration reports exist anywhere online.

How Cholecystokinin (CCK-8) Works

CCK-8 binds two G-protein-coupled receptor subtypes. CCK1 receptors sit mostly in the periphery: gallbladder smooth muscle, pancreatic acinar cells, and vagal afferent nerve terminals lining the stomach and duodenum. CCK2 receptors concentrate in the central nervous system.

When CCK-8 docks with either receptor, it kicks off a Gq/11 signaling cascade. Phospholipase C generates IP3 and DAG. IP3 releases calcium from the endoplasmic reticulum; DAG activates protein kinase C. In pancreatic acinar cells, that calcium surge triggers exocytosis of zymogen granules packed with digestive enzymes. In gallbladder smooth muscle, the same cascade produces contraction and bile ejection.

The satiety pathway runs through CCK1 receptors on vagal afferent nerve endings. Receptor activation fires action potentials up the vagus nerve to the nucleus tractus solitarius in the brainstem. From there, signals relay to hypothalamic feeding centers to suppress appetite and terminate meals. CCK-8 also slows gastric emptying through both vagal reflexes and direct smooth muscle action, keeping nutrients in contact with absorptive epithelium longer.

In the brain, CCK-8 modulates dopaminergic, serotonergic, and GABAergic neurotransmission. The closely related fragment CCK-4 is a validated panicogenic agent in human studies; CCK-8 has weaker anxiogenic properties through CCK2 receptors. Some tissues also see adenylyl cyclase activation via Gs coupling, raising cAMP and activating protein kinase A.

Cholecystokinin (CCK-8) Benefits

  • Cholecystokinin (CCK-8) benefits center on satiety signaling and digestive coordination in controlled research settings.
  • Energy intake at a buffet meal fell as the IV dose rose in 10 healthy men (Brennan et al. 2008)[1].
  • Gallbladder ejection fraction drops 40 to 70 percent within 5 to 15 minutes of IV administration, the basis for its FDA-approved diagnostic use since 1976.
  • Pancreatic enzyme secretion peaks rapidly after CCK1 receptor activation in acinar cells, improving nutrient digestion during research protocols.
  • Gastric emptying delay extends nutrient contact with absorptive epithelium; this mechanism works with leptin and other anorexigenic signals for stronger satiety.
  • Research interest in anxiolytic and pain modulation pathways through CCK2 receptors in the CNS, though human therapeutic applications remain unproven.

Cholecystokinin (CCK-8): Science vs Community Consensus

Science Only
Scientific Evidence
Strong
Based on 10 key studies·FDA-approved

CCK-8 is a validated endogenous satiety hormone with strong IV human evidence for meal termination, gallbladder contraction, and gastric emptying delay.

Dosing studied: 0.02–0.04 mcg/kg IV bolus (1.4–2.8 mcg for 70 kg adult); max infusion protocol 0.12 mcg/kg over 50 min (~8.4 mcg for 70 kg). No validated human SC dosing exists.
Read the evidence (key study, limitations)

Its half-life of about 1.3 min makes it impractical as a therapeutic agent. All validated human administration is IV only. The FDA-approved synthetic equivalent (sincalide/Kinevac) is approved solely for diagnostic gallbladder imaging since 1976.

Key Study

Brennan IM et al. Am J Physiol Endocrinol Metab 2008;295(6):E1487-94; PMID 18957613: dose-dependent effects of CCK-8 on antropyloroduodenal motility, GI hormones, appetite, and energy intake in healthy men (gold-standard human pharmacodynamic study)

Limitations

All validated human data is IV only. No SC bioavailability data in humans. No approved obesity or therapeutic indication for native CCK-8. Extremely short half-life precludes sustained effect. Tachyphylaxis with repeated use via CCK1 receptor desensitization. 2025 research interest has shifted toward long-acting CCK1-selective analogs (not native CCK-8).

Community Experience
Weak
3.5/5
Based on N/A: no community reports found

No community use exists.

Community dosing: N/A: no community dosing data exists
Read the reports (common issues 5)

Zero Reddit threads on r/peptides or r/Nootropics, zero biohacker protocols, zero self-administration reports found. IV-only validated route and a half-life of about 1.3 min create insurmountable practical barriers. No recreational, anabolic, or nootropic appeal.

What users report (0)
    Common issues (5)
    • IV-only validated route: requires clinical or research setting
    • A half-life of about 1.3 min makes SC self-administration impractical even if bioavailability were established
    • No anabolic, nootropic, or body composition applications documented
    • Severe GI side effects (nausea, cramping, urge to defecate) without slow IV infusion
    • Hard contraindications (gallstones, pancreatitis) make unsupervised use particularly dangerous
    Science-Only Evidence

    No community use exists for CCK-8. Scientific evidence for its endogenous role is strong; evidence for exogenous therapeutic application is limited to research settings with IV administration. The compound has no biohacker or self-optimization profile.

    Cholecystokinin (CCK-8) Dosage Guide

    SpeculativeResearch use only; no established injectable human dosing protocol
    LevelDose / InjectionFrequency
    Beginner1 mcgSingle dose
    Moderate2 mcgSingle dose
    Aggressive4 mcgSingle dose
    Note:

    CCK-8 is not a typical research peptide. All validated human dosing is intravenous, and most people encounter it only as sincalide (Kinevac) during a gallbladder imaging study. Gray-market research vials are unsuitable for anything going IV.

    You need the sulfated form (CCK-8S). The sulfated tyrosine at position 7 is required for full CCK1 receptor potency; the non-sulfated version has roughly 1000-fold lower affinity. If satiety and gallbladder effects don't materialize, wrong form is the first thing to check. The Certificate of Analysis names which form a vial contains.

    The only sourced setup comes from the Kinevac label. A 5 mcg vial plus 5 mL of Sterile Water for Injection makes 1 mcg/mL (section 2.2). A 70 kg adult's 0.02 to 0.04 mcg/kg dose is then 1.4 to 2.8 mL.

    No published source gives a stock setup for a 1 mg research vial, which holds 200 times as much peptide.

    Kinevac vials are single use. Keep the mixed vial at room temperature and discard it after 8 hours; a diluted infusion goes after 1 hour (section 2.2). Store lyophilized research powder at -20C desiccated.

    Cycling

    Not cycled. The Kinevac label gives one IV dose per imaging study, plus a second if the gallbladder has not contracted in 15 minutes (section 2.1). No on/off cycle has been published.

    Calculate your Cholecystokinin (CCK-8) dose
    Dosing tiers, timing, and cycle length

    Or use the universal Peptide Calculator for any peptide.

    Cholecystokinin (CCK-8) Protocols by Goal

    advancedClinical TrialSingle session per visit; no published on/off cycle
    IV satiety infusion (pre-meal)
    Wk Single session per study visit. Multi-week daily IV CCK-8 has been tested in patients on total parenteral nutrition, to prevent gallbladder sludge or cholestasis. Adults got 0.05 mcg/kg once daily (PMID 2104681), newborns 0.04 mcg/kg twice daily (PMID 15867044). Neither trial targeted appetite
    0.02–0.04 mcg/kg IV (1.4–2.8 mcg for 70 kg adult) · Single session; can be repeated at successive study visits with adequate intervals · Intravenous: injection over 30–60 seconds, or an infusion to reduce GI effects (Kinevac label, sections 2.1 and 5.3)

    Expected: Reduced energy intake that grows with the dose (PMID 18957613), prolonged intermeal interval, gallbladder volume reduction 40-70%, delayed gastric emptying

    Monitor: Monitor HR, BP, and GI symptoms (nausea, abdominal cramping, urge to defecate) throughout infusion. Have epinephrine available: anaphylaxis risk from sulfite preservatives in some formulations. Verify gallbladder anatomy by ultrasound before use.

    How to Use Cholecystokinin (CCK-8)

    1. 1
      Step 1

      Verify the peptide is CCK-8 sulfated (CCK-8S) with HPLC purity of 98 percent or higher and confirmed molecular weight of 1143.25 Da on the CoA.

    2. 2
      Reconstitute

      The sourced setup is the Kinevac label's: add 5 mL of Sterile Water for Injection to the 5 mcg vial for 1 mcg/mL (section 2.2). No published source gives a stock setup for a 1 mg research vial.

    3. 3
      Calculate your dose

      The label dose is 0.02 mcg/kg, then 0.04 mcg/kg if the gallbladder has not contracted within 15 minutes (section 2.1). For a 70 kg adult, that is 1.4 to 2.8 mcg, or 1.4 to 2.8 mL at 1 mcg/mL.

    4. 4
      Give it as the label does

      The standard is an IV injection over 30 to 60 seconds. Nausea and cramping can occur with that route (section 5.3). To reduce them, the label offers an infusion of 0.12 mcg/kg in 100 mL of 0.9 percent saline over 50 minutes (section 2.1).

    5. 5
      Step 5

      Begin 15 to 30 minutes before meal initiation if studying satiety effects.

    6. 6
      Step 6

      Monitor heart rate and blood pressure continuously throughout the infusion and for 15 minutes after completion. Have epinephrine available for anaphylaxis risk from preservatives. Stop immediately for severe abdominal pain, HR below 50 bpm, or systolic BP below 90 mmHg.

    7. 7
      Step 7

      Needle gauge: use a 27 to 30 gauge needle for drawing from the vial. IV administration requires appropriate IV access.

    8. 8
      Kinevac vials are single use

      Keep the mixed vial at room temperature and discard it after 8 hours; discard a diluted infusion after 1 hour (section 2.2). Keep lyophilized research vials at -20C, protected from light and moisture.

    Alternative Routes

    Subcutaneous

    No human SC bioavailability data available. SC bioavailability likely very low: CCK-8 is rapidly cleaved by plasma peptidases (t½ about 1.3 min IV) and subcutaneous peptidase activity would similarly degrade the peptide before systemic absorption. No dose-equivalency data exists.

    All published human dosing data for CCK-8 is intravenous, and the Kinevac (sincalide) label lists IV use only. No human study has tested SC dosing, so an SC dose cannot be assumed to match an IV dose.

    Oral

    Essentially zero systemic bioavailability via oral route: GI proteases degrade the octapeptide entirely before absorption. This is why the body uses endogenous I-cell CCK secretion rather than circulating CCK from oral intake.

    Dietary proteins and fats trigger endogenous CCK release from intestinal I-cells: this is the physiological equivalent of "oral CCK supplementation" and is not replicable by ingesting exogenous CCK-8.

    Cholecystokinin (CCK-8) Stacking Protocols

    Works With

    Avoid

    Opioid analgesics (morphine, fentanyl, oxycodone, codeine)

    Bidirectional antagonism: opioids inhibit gallbladder contraction peripherally (biliary spasm, elevated sphincter of Oddi tone). CCK-8 also opposes opioid analgesia centrally via CCK2 receptor activation in the spinal cord and brain: reducing opioid analgesic efficacy (PMID 1982023). Interaction is clinically relevant in both directions.

    Do not combine
    Anticholinergic agents (atropine, glycopyrrolate, scopolamine, diphenhydramine)

    Block the downstream parasympathetic pathway through which CCK-8 exerts gallbladder contraction and GI motility effects. Substantially attenuate or abolish efficacy of CCK-8 administration.

    Somatostatin

    Somatostatin inhibits CCK release from duodenal I-cells and suppresses downstream GI responses, opposing satiety and motility effects of exogenous CCK-8.

    Somatostatin analogs (octreotide, lanreotide)

    Same mechanism as native somatostatin: inhibit CCK secretion and blunt GI motility responses. Listed separately because octreotide is commonly used and not in database as a peptide stacking candidate.

    CCK receptor antagonists (loxiglumide, devazepide, proglumide)

    Directly and competitively block CCK1/CCK2 receptors, completely abolishing all pharmacological effects of CCK-8. Used in research as mechanistic controls only.

    Do not combine

    Estimated Cost

    Brand Price
    Kinevac (sincalide for injection, Bracco Diagnostics): hospital/nuclear medicine department use only; ~$200–400/diagnostic kit; not available to consumers or research peptide buyers
    Generic / Research
    Research-grade CCK-8 sulfated, sold only as a lab reagent: ~$100–300/mg. NOT part of the standard research-peptide market. Typically sold in 1-5 mg quantities.

    Pricing updated 2026-04-09

    Cholecystokinin (CCK-8) Side Effects

    The most serious documented risk with CCK-8 is anaphylaxis. Post-marketing surveillance of sincalide (Kinevac) has recorded anaphylactic shock attributed to sodium metabisulfite preservative in some formulations (KINEVAC FDA label, DailyMed). This is rare but potentially fatal, and epinephrine must be available during any administration.

    Gallbladder-related complications deserve equal weight. CCK-8 causes forceful gallbladder contraction. In patients with undiagnosed gallstones, this can dislodge stones into the cystic or common bile duct. The result can be biliary colic, cholangitis, or acute pancreatitis. This is a hard contraindication, not a precaution. Abdominal ultrasound before any CCK-8 use is mandatory.

    At standard diagnostic IV doses, the most common adverse effects are abdominal discomfort and nausea, occurring in over 20 percent of subjects. Higher or bolus doses amplify gastrointestinal symptoms considerably: cramping, vomiting, diarrhea, and a sudden urge to defecate from increased intestinal motility. To reduce them, the Kinevac label offers an infusion in place of the 30 to 60 second IV injection (section 5.3).

    Cardiovascular effects include bradycardia and transient hypotension via vasovagal activation. Heart rate should stay above 50 bpm and systolic blood pressure above 90 mmHg throughout any infusion. Dizziness, flushing, and diaphoresis have been reported.

    Neurological side effects are uncommon. Headache occurs occasionally; seizures are documented but very rare.

    All validated human dosing data is IV only. No human subcutaneous bioavailability data exists. CCK-8 is rapidly cleaved by plasma peptidases, and subcutaneous delivery likely produces negligible systemic levels. The FDA-approved sincalide label specifies IV-only administration.

    The compound's half-life of about 1.3 minutes means most side effects resolve within minutes of stopping the infusion. That rapid clearance is reassuring for acute tolerability but also means CCK-8 simply does not lend itself to repeated self-administration protocols.

    In pregnancy, the Kinevac label warns that sincalide may cause preterm labor or spontaneous abortion through its effect on smooth muscle (sections 5.4 and 8.1). Intestinal obstruction is a label contraindication, and active acute pancreatitis is a hard stop too.

    Stop any infusion immediately for severe abdominal pain, hypotension, bradycardia below 50 bpm, or any sign of allergic reaction. Seek emergency medical care if anaphylaxis is suspected.

    Common Issues & Solutions

    Nausea and abdominal cramping during administration: the Kinevac label links these to IV injection (section 5.3). To reduce them, it gives an infusion of 0.12 mcg/kg in 100 mL of 0.9% saline over 50 minutes (section 2.1).

    Insufficient satiety response: Verify infusion begins 15-30 min before meal (not during or after). Timing relative to meal initiation is critical: the satiety signal must arrive before the cephalic phase terminates.

    Effect duration too short: Expected: half-life is about 1.3 min and the direct peptide effect is brief. Downstream neural satiety signaling via the vagus-NTS-hypothalamic axis persists beyond peptide clearance. If longer effect is needed, use continuous infusion rather than bolus.

    Gallbladder pain during or after infusion: Stop immediately and assess for stone dislodgement. Biliary colic, cholangitis, or acute pancreatitis are possible sequelae. Ultrasound should rule out cholelithiasis before any CCK-8 administration.

    Insufficient biological activity: Confirm the material is the sulfated form (CCK-8S): the sulfated tyrosine at position 7 (Tyr(SO3H)-Met-Gly-Trp-Met-Asp-Phe-NH2) is required for full CCK1 receptor potency. Non-sulfated CCK-8 has ~1000-fold lower CCK1 affinity.

    Ask AI about this page

    Ask AI for a second opinion on Cholecystokinin (CCK-8) dosing and side effects

    Contraindications

    • Intestinal obstruction (CCK-8 increases intestinal motility and could worsen obstruction)
    • Known hypersensitivity to sincalide or sulfite-containing preparations
    • Gallbladder stones (risk of stone dislodgement into cystic or common bile duct)
    • Pregnancy: not a label contraindication, but the Kinevac label warns of preterm labor or spontaneous abortion (sections 5.4 and 8.1)
    • Active acute pancreatitis (CCK-8 stimulates pancreatic secretion and could exacerbate inflammation)

    Drug Interactions

    • Opioid analgesics (morphine, fentanyl): inhibit gallbladder contraction and oppose CCK-8 effects on biliary motility for up to 18 hours
    • Anticholinergic agents (atropine, glycopyrrolate): may attenuate CCK-8-mediated gallbladder contraction and gastrointestinal motility
    • CCK receptor antagonists (loxiglumide, devazepide): directly block CCK1/CCK2 receptor activation and abolish CCK-8 effects
    • Somatostatin analogs (octreotide): inhibit CCK release and may blunt downstream GI responses
    • Bidirectional antagonism: opioids inhibit gallbladder contraction peripherally (biliary spasm, elevated sphincter of Oddi tone). CCK-8 also opposes opioid analgesia centrally via CCK2 receptor activation in the spinal cord and brain: reducing opioid analgesic efficacy (PMID 1982023). Interaction is clinically relevant in both directions.

    Product Quality

    Recommended Monitoring

    TestWhenTarget
    Abdominal ultrasound (gallbladder)Before any CCK-8 administrationNo gallstones present; normal gallbladder wall thickness and anatomy
    Vital signs (heart rate, blood pressure)Continuously throughout IV infusion and 15 min post-infusionHR >50 bpm, systolic BP >90 mmHg throughout infusion
    Serum lipase and amylaseIf abdominal pain develops during or within 6 hours of infusionLipase <3× upper limit of normal; amylase within normal limits
    Abdominal ultrasound (gallbladder)

    Rule out cholelithiasis: gallstones are a hard contraindication. CCK-8-induced forceful gallbladder contraction can dislodge stones into the cystic or common bile duct, causing biliary colic, cholangitis, or acute pancreatitis.

    Vital signs (heart rate, blood pressure)

    Bradycardia and transient hypotension can occur via vasovagal mechanism with CCK-8 administration. Anaphylaxis surveillance required: most dangerous in first 5-10 min.

    Serum lipase and amylase

    CCK-8 stimulates pancreatic secretion; in susceptible individuals (subclinical pancreatitis, pancreas divisum, high-dose administration) it can trigger acute pancreatitis.

    Cholecystokinin (CCK-8) Before and After

    0-5 minutes

    Onset of gallbladder contraction and initial satiety signaling following IV administration

    5-15 minutes

    Peak gallbladder contraction (40-70% reduction in volume); maximal suppression of appetite and gastric emptying

    15-30 minutes

    Effects begin to wane as CCK-8 is rapidly cleared from plasma; meal-related satiety persists via downstream neural signaling

    30-60 minutes

    Return to baseline gastrointestinal motility; CCK levels normalize to pre-administration values

    What to Expect

    0 to 5 minutes: Gallbladder contraction starts within 1 to 2 minutes of IV infusion onset. Vagal CCK1 receptors begin transmitting satiety signals to the brainstem nucleus tractus solitarius. A mild heart rate dip may occur through the vasovagal pathway. Some subjects feel abdominal fullness; nausea is likely if the dose was pushed too fast as a bolus. No community user reports exist for this compound.

    5 to 15 minutes: Peak effects hit. Gallbladder volume drops 40 to 70 percent from baseline. Appetite suppression and gastric emptying delay reach maximum intensity. Pancreatic enzyme secretion peaks and the sphincter of Oddi relaxes. Energy intake reduction becomes measurable in controlled meal studies. Nausea, abdominal cramping, and the urge to defecate are most pronounced in this window, especially with bolus dosing. Dizziness and flushing can occur.

    15 to 30 minutes: Plasma CCK-8 is already cleared given its half-life of about 1.3 minutes. Direct GI contractile effects start fading. The downstream neural satiety signal, running through the vagus to the NTS to the hypothalamus, persists beyond peptide clearance. Most GI side effects begin resolving; some residual fullness may linger.

    30 to 60 minutes: GI motility, gastric emptying rate, and gallbladder volume return toward baseline. Meal-related satiety may persist via downstream signaling even though the peptide itself is long gone. From a pharmacokinetic standpoint, CCK-8 is functionally absent from circulation well before this window. Any remaining side effects have typically resolved.

    Detailed Timeline: Science vs Community

    0–5 min
    Science

    Gallbladder contraction begins within 1-2 min of IV infusion start. Vagal afferent CCK1 receptor activation transmits satiety signals to nucleus tractus solitarius. Mild HR decrease may occur via vasovagal mechanism.

    Community

    No community reports available: compound has no self-administration history.

    5–15 min
    Science

    Gallbladder volume reduces 40-70% from baseline. Maximal appetite suppression and gastric emptying delay. Pancreatic enzyme secretion peaks. Sphincter of Oddi relaxes. Energy intake reduction detectable in meal studies.

    Community

    No community reports available.

    15–30 min
    Science

    Plasma CCK-8 cleared (t½ about 1.3 min). Direct GI contractile effects wane. Downstream neural satiety signals persist beyond peptide clearance via vagal-NTS-hypothalamic axis activation.

    Community

    No community reports available.

    30–60 min
    Science

    GI motility, gastric emptying rate, and gallbladder volume return toward pre-infusion baseline. Meal-related satiety may persist beyond peptide clearance via downstream signaling. Energy intake suppression documented through end of meal.

    Community

    No community reports available.

    Pharmacokinetics

    Half-Life
    1min
    Bioavailability
    IV: ~100%; SC: not well-characterized, estimated low due to rapid enzymatic degradation
    Tmax
    IV bolus: 1-2 min; IV infusion: end of infusion; SC: no human data
    Data Confidence
    moderate

    Source: Kanayama et al. Am J Gastroenterol 1985; PMID 4014106: CCK-8 disappearance half-time 1.30 min after a 2-minute IV infusion in healthy adults (1.70 min in chronic renal failure, 2.45 min in cirrhosis). CCK-33 clears more slowly: elimination t½ 4.2 min IV (Jebbink et al. 1990, PMID 2378793)

    Pharmacokinetics: Active Dose Over Time

    t½ = ~1.3 minutes (IV, CCK-8)

    Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.

    Molecular Profile

    Amino Acids
    8
    Sequence
    DYMGWMDF
    HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
    Identifiers
    CAS: 25126-32-3 (CCK-8 sulfated)PubChem 9833444 (opens in a new tab)

    Who Should Consider Cholecystokinin (CCK-8)

    • Appetite and satiety researchers
    • Gastrointestinal motility investigators
    • Obesity and metabolic disorder researchers
    • Neuroscience researchers studying anxiety and panic
    • Gastroenterologists evaluating gallbladder function
    • Pain and nociception researchers

    Related Peptides

    What Changed for Cholecystokinin (CCK-8)

    1. Evidence

      Corrected Oct 18, 2026: CCK-8's half-life is about 1.3 minutes after IV dosing in healthy adults, not 2 to 5 minutes, per Kanayama 1985.

      Before: The compound's 2 to 5 minute half-life means most side effects resolve within minutes of stopping the infusion. After: The compound's half-life of about 1.3 minutes means most side effects resolve within minutes of stopping the infusion.

      What this does not mean: No new safety finding. The page's 2 to 5 minutes had no CCK-8 source; the 4.2 minutes it cited (Jebbink 1990) was measured for CCK-33. Clearance was slower in cirrhosis (2.45 min).

      Source: Kanayama et al., Am J Gastroenterol 1985;80(7):557-60, PMID 4014106 (CCK-8 disappearance half-time after a 2-minute IV infusion: 1.30 min healthy, 1.70 min chronic renal failure, 2.45 min cirrhosis) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)

    2. Safety

      Corrected Oct 14, 2026: CCK-8 may cause preterm labor or miscarriage, a label warning, and an infusion eases its GI effects, per the Kinevac label.

      Before: Pregnancy is contraindicated (preterm labor, spontaneous abortion); a 30 to 50 minute infusion and a dilution step presented as required After: Pregnancy: label warning of preterm labor or spontaneous abortion (5.4, 8.1); the label offers an infusion to reduce GI effects (5.3)

      What this does not mean: Pregnancy still carries the warning (sections 5.4 and 8.1). The page had called pregnancy a contraindication and blamed failed protocols on a skipped dilution step; the label says neither.

      Source: Kinevac (sincalide) prescribing information (openFDA label record, SPL version 13, effective Oct 18, 2023; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

    3. Safety

      Corrected Oct 14, 2026: pregnancy is a label warning for CCK-8 (sincalide), not a contraindication, per the Kinevac label, sections 4, 5.4 and 8.1.

      Before: Pregnancy (risk of preterm labor and spontaneous abortion due to smooth muscle stimulation) After: Pregnancy: not a label contraindication, but the Kinevac label warns of preterm labor or spontaneous abortion (sections 5.4 and 8.1)

      What this does not mean: Sincalide may cause preterm labor or spontaneous abortion, so pregnancy stays on the list as a warning. The label contraindications are sulfite or sincalide hypersensitivity and intestinal obstruction.

      Source: Kinevac (sincalide) prescribing information (openFDA label record, SPL version 13, effective Oct 18, 2023; captured as the same-version DailyMed SPL XML) (opens in a new tab) · Saved copy

    4. Regulatory

      Corrected Oct 10, 2026: CCK-8 now lists two sincalide applications, Kinevac (NDA 017697, 1976) and NDA 210850 (2022), both prescription, per Drugs@FDA.

      Before: No sourced US status record After: US status FDA approved: Kinevac NDA 017697 (Jul 21, 1976) and sincalide NDA 210850 (Nov 22, 2022), both prescription

      What this does not mean: Both applications are for the same IV diagnostic drug. Neither covers appetite, weight loss or any other therapeutic use.

      Source: Drugs@FDA record for sincalide, NDA 210850 (openFDA): original approval Nov 22, 2022; prescription (opens in a new tab) · Saved copy

    5. Regulatory

      Corrected Oct 10, 2026: CCK-8's status now reflects FDA's Jul 21, 1976 original approval of sincalide as Kinevac (NDA 017697), not research only, per Drugs@FDA.

      Before: Research only After: FDA Approved (as sincalide: Kinevac, NDA 017697, Jul 21, 1976)

      What this does not mean: The approval covers sincalide as an IV diagnostic for gallbladder and pancreas testing. It does not cover appetite, weight loss or research vials of CCK-8.

      Source: Drugs@FDA record for Kinevac (sincalide), NDA 017697 (openFDA): original approval Jul 21, 1976; prescription (opens in a new tab) · Saved copy

    6. Regulatory

      Corrected Oct 10, 2026: CCK-8's research stage moves from preclinical to FDA approval, after sincalide's Jul 21, 1976 Kinevac approval, per Drugs@FDA.

      Before: Preclinical After: Approved (sincalide, Kinevac NDA 017697)

      What this does not mean: It reflects the sincalide diagnostic approval only. Appetite and weight-loss use of CCK-8 is limited to IV research studies in people.

      Source: Drugs@FDA record for Kinevac (sincalide), NDA 017697 (openFDA): original approval Jul 21, 1976; prescription (opens in a new tab) · Saved copy

    Peptide Schedule Research TeamReviewed Apr 8, 202610 Citations

    References

    1. [1]Dose-dependent effects of cholecystokinin-8 on antropyloroduodenal motility, gastrointestinal hormones, appetite, and energy intake in healthy men (Am J Physiol Endocrinol Metab 2008) (opens in a new tab)PubMed (opens in a new tab)PubMed
    2. [2]Cholecystokinin: portrayal of an unfolding peptide messenger system (Rehfeld et al., Peptides 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed

    Related Tools

    Storage & Stability

    Before Reconstitution
    Stable for 2-3 years when stored desiccated at -20°C; protect from light and moisture
    After Reconstitution
    Kinevac (label section 2.2): single use; keep the mixed vial at room temperature and discard after 8 hours, and discard a diluted infusion after 1 hour. No sourced stability data exists for mixed research vials.
    Temperature
    -20°C for lyophilized research vials; Kinevac vials at 25°C (77°F) per its label

    Frequently Asked Questions

    No published human data supports SC administration. All validated human dosing is IV. The peptide is rapidly degraded by plasma proteases, and SC delivery may produce negligible systemic levels. The diagnostic analog sincalide is IV-only per FDA labeling.

    CCK-8 is rapidly cleaved by circulating peptidases including procollagen C-endopeptidase and other serum proteases. This reflects normal physiology. CCK is a meal-triggered hormone designed for burst signaling, not sustained circulation.

    The closely related fragment CCK-4 (the C-terminal tetrapeptide) is a well-established panicogenic agent in research. CCK-8 has anxiogenic properties at CNS CCK2 receptors but this effect is far weaker than CCK-4. Elevated CCK tone is associated with panic disorder pathophysiology.

    Yes, sincalide is the synthetic C-terminal octapeptide of CCK, identical to CCK-8. Kinevac (sincalide for injection) has been FDA-approved since 1976 for gallbladder function testing.

    CCK-8 causes forceful gallbladder contraction. In patients with gallstones this can dislodge stones into the cystic duct or common bile duct, causing biliary colic, cholangitis, or acute pancreatitis. This is a hard contraindication. Not a precaution.